[Current therapeutic aspects of myasthenia gravis].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004809:Ephedrine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000150:complications / Q000532:radiotherapy / Q000628:therapy*; D010956:Plasmapheresis; D013897:Thoracic Duct / Q000601:surgery; D013934:Thymectomy; D013945:Thymoma / Q000150:complications; D013953:Thymus Neoplasms / Q000150:complications
D000305:Adrenal Cortex Hormones; D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents; D001285:Atropine; D000324:Adrenocorticotropic Hormone; D004809:Ephedrine
Aspectos terapéuticos actuales de la miastenia gravis.